Goldfinch Bio Aims $55M and Cancer Strategy at Genetic Kidney Disease

Dec 14, 2016, 09:35 AM by Michael Croft

Xconomy | Chronic kidney disease affects more than 10 percent of U.S. adults, and the risk of developing the condition increases with age. New biotech Goldfinch Bio wants to turn genetic research into new therapies.

December 14, 2016 | Chronic kidney disease affects more than 10 percent of U.S. adults, and the risk of developing the condition increases with age. New biotech Goldfinch Bio wants to turn genetic research into new therapies. Xconomy